Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
NCT ID: NCT00241462
Last Updated: 2009-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
150 participants
OBSERVATIONAL
2005-06-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)
NCT00880711
Faslodex Specific Clinical Experience Investigation
NCT01501266
Faslodex Registry: Fulvestrant in Current Clinical Practice
NCT00735215
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)
NCT01509625
A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
NCT02447328
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status
* Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca Netherlands Medical Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Alkmaar, , Netherlands
Research Site
Almelo, , Netherlands
Research Site
Almere Stad, , Netherlands
Research Site
Amsterdam, , Netherlands
Research Site
Apeldoorn, , Netherlands
Research Site
Assen, , Netherlands
Research Site
Bergen op Zoom, , Netherlands
Research Site
Capelle aan den IJssel, , Netherlands
Research Site
Delft, , Netherlands
Research Site
Delfzijl, , Netherlands
Research Site
Doetinchem, , Netherlands
Research Site
Dokkum, , Netherlands
Research Site
Dordrecht, , Netherlands
Research Site
Drachten, , Netherlands
Research Site
Ede Gld, , Netherlands
Research Site
Eindhoven, , Netherlands
Research Site
Geldrop, , Netherlands
Research Site
Gorinchem, , Netherlands
Research Site
Hardenberg, , Netherlands
Research Site
Heerenveen, , Netherlands
Research Site
Heerlen, , Netherlands
Research Site
Hellevoetsluis, , Netherlands
Research Site
Hilversum, , Netherlands
Research Site
Hoogeveen, , Netherlands
Research Site
Leiden, , Netherlands
Research Site
Leiderdorp, , Netherlands
Research Site
Leidschendam, , Netherlands
Research Site
Meppel, , Netherlands
Research Site
Nieuwegein, , Netherlands
Research Site
Oss, , Netherlands
Research Site
Roermond, , Netherlands
Research Site
Rotterdam, , Netherlands
Research Site
Stadskanaal, , Netherlands
Research Site
Terneuzen, , Netherlands
Research Site
The Hague, , Netherlands
Research Site
Tilburg, , Netherlands
Research Site
Utrecht, , Netherlands
Research Site
Vlaardingen, , Netherlands
Research Site
Winschoten, , Netherlands
Research Site
Winterswijk, , Netherlands
Research Site
Zeist, , Netherlands
Research Site
Zevenaar, , Netherlands
Research Site
Zwolle, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FORUM
Identifier Type: -
Identifier Source: secondary_id
D6997-NL-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.